IPG Photonics to Acquire Lumibird Medical for €300M, Expanding Medical Laser Portfolio — IPG Photonics Corporation

Event summary

IPG Photonics has made a binding offer to acquire Lumibird Medical for €300 million, with an additional €50 million earnout contingent on performance metrics.
The acquisition is expected to close in Q4 2026, subject to regulatory approvals and completion of the information and consultation process with Lumibird Medical's works council.
Lumibird Medical reported revenue of €112.2 million and EBITDA of €24.1 million for the fiscal year ended December 31, 2025, with an EBITDA margin of 21.5%.
The deal aims to create a scaled medical laser platform, combining IPG’s strength in urology with Lumibird Medical’s leadership in ophthalmology.

The big picture

This acquisition aligns with IPG Photonics’ strategy to expand its Advanced Solutions portfolio in high-growth medical markets. The deal underscores the trend of consolidation in the medical laser sector, driven by the need for scale and innovation. With Lumibird Medical’s strong presence in ophthalmology complementing IPG’s expertise in urology, the combined entity aims to deliver differentiated solutions and capture a larger share of the non-discretionary spending-driven market.

What we're watching

Integration Challenges: How IPG Photonics will integrate Lumibird Medical’s operations and retain key talent, given the cultural and operational differences.
Market Expansion: Whether the combined entity can effectively tap into the €1 billion addressable market for advanced medical laser solutions.
Financial Impact: The pace at which the acquisition will deliver accretive benefits to IPG’s gross margin, EBITDA, and adjusted EPS.